Nakanishi (7716) Fundamentals 2026 — P/E 215.6x, Revenue Analysis | SniperIQ
Nakanishi (7716) is a JP-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ¥252.5B, trading at ¥3040.00 on the JPX. This SniperIQ fundamentals page covers Nakanishi's valuation (P/E 215.6x, P/B 2.2x), profitability (net margin 1.3%), revenue (¥81.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Nakanishi's market cap?
Nakanishi (7716) has a market capitalization of approximately ¥252.5B, trading at ¥3040.00 on the JPX. Market cap moves with the live share price.
What is Nakanishi's P/E ratio?
Nakanishi's trailing twelve-month P/E ratio is 215.6x, with a price-to-book (P/B) of 2.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Nakanishi?
Nakanishi runs a net profit margin of 1.3%, a gross margin of 54.8%, and an operating margin of 18.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Nakanishi generate?
Nakanishi reported revenue of ¥81.2B for fiscal year 2025, with net income of -¥2.4B and earnings per share (EPS) of -28.7. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Nakanishi pay a dividend?
Nakanishi offers a trailing dividend yield of about 1.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Nakanishi financially healthy?
Nakanishi carries a debt-to-equity ratio of 0.28x and a current ratio of 3.07x, with a market beta of 0.10. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Nakanishi a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Nakanishi (7716) the key facts are: market cap ¥252.5B, P/E 215.6x, revenue ¥81.2B, 52-week range 1900-3180. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Nakanishi's full fundamentals live
Get Nakanishi's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.